These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9181641)

  • 1. Flesinoxan pretreatment differentially affects corticosterone, prolactin and behavioural responses to a flesinoxan challenge.
    Groenink L; Van der Gugten J; Compaan JC; Maes RA; Olivier B
    Psychopharmacology (Berl); 1997 May; 131(1):93-100. PubMed ID: 9181641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anxiolytic effects of flesinoxan, a 5-HT1A receptor agonist, are not related to its neuroendocrine effects.
    Groenink L; Van der Gugten J; Verdouw PM; Maes RA; Olivier B
    Eur J Pharmacol; 1995 Jul; 280(2):185-93. PubMed ID: 7589185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment with 5-HT1A receptor agonist flesinoxan attenuates Fos protein in rat hypothalamus.
    Compaan JC; Groenink L; Van der Gugten J; Maes RA; Olivier B
    Eur J Pharmacol; 1997 Apr; 324(2-3):161-8. PubMed ID: 9145767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flesinoxan treatment reduces 5-HT1A receptor mRNA in the dentate gyrus independently of high plasma corticosterone levels.
    Sibug RM; Compaan JC; Meijer OC; Van der Gugten J; Olivier B; De Kloet ER
    Eur J Pharmacol; 1998 Jul; 353(2-3):207-14. PubMed ID: 9726650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The corticosterone-enhancing effects of the 5-HT1A receptor antagonist, (S)-UH301, are not mediated by the 5-HT1A receptor.
    Groenink L; Van der Gugten J; Mos J; Maes RA; Olivier B
    Eur J Pharmacol; 1995 Jan; 272(2-3):177-83. PubMed ID: 7713161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic modelling of the hypothermic and corticosterone effects of the 5-HT1A receptor agonist flesinoxan.
    Zuideveld KP; van Gestel A; Peletier LA; Van der Graaf PH; Danhof M
    Eur J Pharmacol; 2002 Jun; 445(1-2):43-54. PubMed ID: 12065193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-HT1A receptors and the tail-flick response. VI. Intrinsic alpha 1A-adrenoceptor antagonist properties can mask the actions of 5-HT1A receptor agonists in the spontaneous tail-flick paradigm.
    Millan MJ; Rivet JM; Gobert A; Canton H; Veiga S; Bervoets K
    J Pharmacol Exp Ther; 1994 Apr; 269(1):121-31. PubMed ID: 7909555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of the 5-HT1A agonist flesinoxan, in three paradigms for assessing antidepressant potential in the rat.
    Cryan JF; Redmond AM; Kelly JP; Leonard BE
    Eur Neuropsychopharmacol; 1997 May; 7(2):109-14. PubMed ID: 9169298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of flesinoxan on corticosteroid receptor expression in the rat hippocampus.
    Sibug RM; Compaan JC; Meijer OC; Van der Gugten J; Olivier B; De Kloet ER
    Eur J Pharmacol; 2000 Sep; 404(1-2):111-9. PubMed ID: 10980269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of 5-HT1A receptor agonists, 5-HT1A receptor antagonists and their interaction on the fear-potentiated startle response.
    Joordens RJ; Hijzen TH; Olivier B
    Psychopharmacology (Berl); 1998 Oct; 139(4):383-90. PubMed ID: 9809859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WAY-100635 inhibits 8-OH-DPAT-stimulated oxytocin, ACTH and corticosterone, but not prolactin secretion.
    Vicentic A; Li Q; Battaglia G; Van de Kar LD
    Eur J Pharmacol; 1998 Apr; 346(2-3):261-6. PubMed ID: 9652368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypothalamic paraventricular nucleus lesions differentially affect serotonin-1A (5-HT1A) and 5-HT2 receptor agonist-induced oxytocin, prolactin, and corticosterone responses.
    Bagdy G; Makara GB
    Endocrinology; 1994 Mar; 134(3):1127-31. PubMed ID: 8119151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of 5-hydroxytryptamine1A properties of flesinoxan: in vivo electrophysiology and hypothermia study.
    Hadrava V; Blier P; Dennis T; Ortemann C; de Montigny C
    Neuropharmacology; 1995 Oct; 34(10):1311-26. PubMed ID: 8570029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a 5-HT(1A) receptor agonist, flesinoxan, on the extracellular noradrenaline level in the hippocampus and on the locomotor activity of rats.
    Suwabe A; Kubota M; Niwa M; Kobayashi K; Kanba S
    Brain Res; 2000 Mar; 858(2):393-401. PubMed ID: 10708692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine effects of diazepam and flesinoxan in the stress-induced hyperthermia test in mice.
    Groenink L; van der Gugten J; Zethof TJ; van der Heyden JA; Olivier B
    Pharmacol Biochem Behav; 1996 May; 54(1):249-54. PubMed ID: 8728565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discriminative stimulus effect of flesinoxan: effect of 5-HT1A antagonists and PCPA.
    Ybema CE; Slangen JL; Olivier B
    Pharmacol Biochem Behav; 1994 Apr; 47(4):957-62. PubMed ID: 8029269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long lasting attenuation of 8-OH-DPAT-induced corticosterone secretion after a single injection of a 5-HT1A receptor agonist.
    Kelder D; Ross SB
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Aug; 346(2):121-6. PubMed ID: 1448177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The renal functional responses to 5-HT1A receptor agonist, flesinoxan, in anaesthetized, normotensive rat.
    Chamienia AL; Johns EJ
    Br J Pharmacol; 1994 May; 112(1):214-8. PubMed ID: 8032644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The putative 5-HT1A receptor antagonist DU125530 blocks the discriminative stimulus of the 5-HT1A receptor agonist flesinoxan in pigeons.
    Mos J; Van Hest A; Van Drimmelen M; Herremans AH; Olivier B
    Eur J Pharmacol; 1997 May; 325(2-3):145-53. PubMed ID: 9163561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 5-HT1A receptor agonist flesinoxan increases aversion in a model of panic-like anxiety in rats.
    Jenck F; Martin JR; Moreau JL
    J Psychopharmacol; 1999; 13(2):166-70. PubMed ID: 10475723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.